RxDoctor Payments Data

Molly Thompson, DO

Emergency Medicine · Nevada, IANPI 1053981241

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Bayer at 30.3% of the total. Reporting peaked in 2022 at $96 and has fallen 81.6% since, to $18 in 2024. Among emergency medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$240in general payments, 2019–2025

Across 15 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$73
  • AbbVie$55
  • Grifols USA, LLC$31
  • Boehringer Ingelheim$17
  • Exact Sciences$17
  • Amarin Pharma, Inc.$17
  • plus $30 from 3 others

What the payments were for

  • Food & beverage$240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$240 in reported general payments places this provider in the 90th percentile of 360 emergency medicine providers in Iowa.

See all emergency medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$80,279
Medicare patients
209
Services billed
2,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$17,826
EliquisApixaban20$16,902
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,367
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,816
Gabapentin48$958
Omeprazole68$761
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$609
Atorvastatin Calcium74$531
Levothyroxine Sodium58$503
Tramadol Hcl54$392
Metoprolol Succinate28$307
Losartan Potassium27$300
Simvastatin49$294
Albuterol Sulfate HfaAlbuterol Sulfate11$294
Metformin Hcl32$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$17$17,82620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 360 emergency medicine providers in Iowa.

Other emergency medicine in Nevada

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →